Lewetiracetam i leczenie padaczki w szczególnych sytuacjach klinicznych

• Authors: Karol Jastrzębski , Magdalena Justyna Kacperska

Title variants

EN

Levetiracetam and therapy of epilepsy in specific clinical situations

• Languages of publication: PL

Abstracts

PL

Padaczka (epilepsia) to przewlekłe i częste schorzenie neurologiczne, wymagające długotrwałego stosowania leków przeciwpadaczkowych. Liczne i złożone objawy tego skomplikowanego procesu patofizjologicznego są wynikiem różnych zaburzeń funkcji mózgu. W leczeniu padaczki nie występuje jeden standardowy sposób postępowania. Głównym i podstawowym celem leczenia padaczki jest całkowita kontrola napadów i zminimalizowanie objawów niepożądanych spowodowanych terapią lekami przeciwpadaczkowymi. Ogromne znaczenie ma indywidualne dopa­sowanie leku do każdego pacjenta. Lek powinien być dostosowany do typu napadu lub zespołu padaczkowego, czę­stości i ciężkości napadów. Pojawienie się leków nowej generacji dało im pewną przewagę w stosunku do leków starszej generacji. Jednym z dostępnych na rynku leków przeciwpadaczkowych jest lewetiracetam, występujący w postaci podłużnych tabletek. Można go stosować w monoterapii u pacjentów od 16. roku życia z nowo rozpoznaną padaczką, w leczeniu napadów padaczkowych o początku ogniskowym z wtórnym uogólnieniem lub bez wtórnego uogólnienia. Lewetiracetam można również dodawać do terapii innymi lekami przeciwpadaczkowymi, w leczeniu m.in. napadów padaczkowych o początku ogniskowym z wtórnym uogólnieniem lub bez wtórnego uogólnienia u dzieci od 1 mie­siąca życia, drgawek mioklonicznych (u pacjentów w wieku powyżej 12 lat z młodzieńczą padaczką miokloniczną) czy pierwotnych uogólnionych napadów toniczno-klonicznych u pacjentów powyżej 12 lat z idiopatyczną pa­daczką uogólnioną. Lek ten między innymi pomaga w stabilizowaniu aktywności elektrycznej w mózgu i zapo­biega napadom.

EN

Epilepsy is a chronic, frequently encountered neurological disease, demanding long-term treatment with antiepi­leptic drugs (AEDs). It involves high treatment expenses. Epilepsy is a complex pathophysiological process, the numerous and complex symptoms are the result of various disorders of the brain. In the treatment of epilepsy, there is no one standard way to proceed. The main and primary goal of epilepsy treatment is complete seizure control and getting the least side effects during treatment with antiepileptic drugs. It is vital that individual adjustment of the drug for each patient. The drug should be adapted to the type of seizure or seizure team, the frequency and severity of seizures. The emergence of a new generation of drugs gave them a certain advantage over the older generation drugs. Levetiracetam is one of the antiepileptic drugs – the pharmacokinetic profile of levetiracetam has been evaluated in many populations. Overall, levetiracetam has a very favourable pharmacokinetic profile, with rapid absorption following oral administration, excellent bioavailability, quick achievement of steady-state concen­trations, linear kinetics, minimal plasma protein binding and without important hepatic metabolism. The mecha­nism of actions is still unclear. It may be used as monotherapy in patients with newly diagnosed epilepsy, to treat seizures with focal onset with secondary generalization or without secondary generalization. Levetiracetam may also be used supplementary to other antiepileptic drugs in the treatment of seizures of focal onset with secondary generalization or without secondary generalization, myoclonic seizures or primary generalized tonic-clonic seizure. This medicine is very useful tool for clinicians.

Keywords

EN

antiepileptic drugs; cytokiny prozapalne; epilepsy; epileptogenesis; epileptogeneza; farmakokinetyka; inflammation; leki przeciwpadaczkowe; levetiracetam; lewetiracetam; padaczka; pathogenesis; patomechanizm; pharmacokinetics; pro-inflammatory cytokins; terapia padaczki; treatment of epilepsy; zapalenie

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2013
• Volume: 13
• Issue: 4
• Pages: 258–266

Contributors

author

Karol Jastrzębski

• Klinika Neurologii i Epileptologii z Oddziałem Udarowym Uniwersyteckiego Szpitala Klinicznego im. WAM, Uniwersytet Medyczny w Łodzi

author

Magdalena Justyna Kacperska

• Klinika Neurologii i Epileptologii z Oddziałem Udarowym Uniwersyteckiego Szpitala Klinicznego im. WAM, Uniwersytet Medyczny w Łodzi

References

• 1. Cendrowski W.: Neuroepidemiologia kliniczna. Volumed, Wro­cław 1997.
• 2. Nadkarni S., LaJoie J., Devinsky O.: Current treatments of epi­lepsy. Neurology 2005; 64 (12 supl. 3): S2–S11.
• 3. Ashhab M.U., Omran A., Kong H. i wsp.: Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial tem­poral lobe epilepsy. J. Mol. Neurosci. 2013; 51: 950–958.
• 4. Voutsinos-Porche B., Koning E., Kaplan H. i wsp.: Temporal patterns of the cerebral inflammatory response in the rat lith­ium-pilocarpine model of temporal lobe epilepsy. Neurobiol. Dis. 2004; 17: 385–402.
• 5. Lehtimäki K.A., Liimatainen S., Peltola J., Arvio M.: The serum level of interleukin-6 in patients with intellectual disabil­ity and refractory epilepsy. Epilepsy Res. 2011; 95: 184–187.
• 6. Kim J.E., Choi H.C., Song H.K. i wsp.: Levetiracetam inhib­its interleukin-1 beta inflammatory responses in the hippo­campus and piriform cortex of epileptic rats. Neurosci. Lett. 2010; 471: 94–99.
• 7. Rijkers K., Majoie H.J., Hoogland G. i wsp.: The role of inter­leukin-1 in seizures and epilepsy: a critical review. Exp. Neu­rol. 2009; 216: 258–271.
• 8. French J.A., Kanner A.M., Bautista J. i wsp.; Therapeutics and Technology Assessment Subcommittee of the American Acad­emy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society: Efficacy and tolerability of the new antiepileptic drugs II: treat­ment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–1273.
• 9. French J.A., Kanner A.M., Bautista J. i wsp.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Ther­apeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurolo­gy 2004; 62: 1252–1260.
• 10. Kacperska M.J., Jastrzębski K., Kozera-Kępiniak A., Klimek A.: Wybrane farmakokinetyczne interakcje leków w trakcie leczenia padaczki. Część I. Aktualn. Neurol. 2013; 13: 40–49.
• 11. Jastrzębski K., Kacperska M.J., Kozera-Kępiniak A., Klimek A.: Wybrane farmakokinetyczne interakcje leków w trakcie lecze­nia padaczki. Część II. Aktualn. Neurol. 2013; 13: 50–55.
• 12. Perucca E., French J., Bialer M.: Development of new antiep­ileptic drugs: challenges, incentives, and recent advances. Lan­cet Neurol. 2007; 6: 793–804.
• 13. Elger C.E., Fernández G.: Options after the first antiepileptic drug has failed. Epilepsia 1999; 40 supl. 6: S9–S12; discus­sion S73–S74.
• 14. Berg M.J.: What’s the problem with generic antiepileptic drugs? A call to action. Neurology 2007; 68: 1245–1246.
• 15. Liow K., Barkley G.L., Pollard J.R. i wsp.; American Academy of Neurology: Position statement on the coverage of anticon­vulsant drugs for the treatment of epilepsy. Neurology 2007; 68: 1249–1250.
• 16. Crawford P., Feely M., Guberman A., Kramer G.: Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006; 15: 165–176.
• 17. Gower A.J., Noyer M., Verloes R. i wsp.: ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 1992; 222: 193–203.
• 18. Shorvon S.: Pyrrolidone derivatives. Lancet 2001; 358: 1885–1892.
• 19. Obeso J.A., Artieda J., Luquin M.R. i wsp.: Antimyoclonic action of piracetam. Clin. Neuropharmacol. 1986; 9: 58–64.
• 20. Fedi M., Reutens D., Dubeau F. i wsp.: Long-term efficacy and safety of piracetam in the treatment of progressive myoc­lonus epilepsy. Arch. Neurol. 2001; 58: 781–786.
• 21. Löscher W., Hönack D.: Profile of ucb L059, a novel anticon­vulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 1993; 232: 147–158.
• 22. Klitgaard H., Matagne A., Gobert J., Wülfert E.: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998; 353: 191–206.
• 23. Kasteleijn-Nolst Trenite D.G., i wsp.: Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. 1996; 25: 225–230.
• 24. Noyer M., Gillard M., Matagne A. i wsp.: The novel antiepilep­tic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 1995; 286: 137–146.
• 25. Sills G.J., Leach J.P., Fraser C.M. i wsp.: Neurochemical stud­ies with the novel anticonvulsant levetiracetam in mouse brain. Eur. J. Pharmacol. 1997; 325: 35–40.
• 26. Margineanu D.G., Wülfert E.: Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. 1997; 122: 1146–1150.
• 27. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G.: Selective block­ade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18.
• 28. Fuks B., Gillard M., Michel P. i wsp.: Localization and pho­toaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 2003; 478: 11–19.
• 29. Lynch B.A., Lambeng N., Nocka K. i wsp.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug leveti­racetam. Proc. Natl Acad. Sci. USA 2004; 101: 9861–9866.
• 30. Doheny H.C., Ratnaraj N., Whittington M.A. i wsp.: Blood and cerebrospinal fluid pharmacokinetics of the novel anti­convulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999; 34: 161–168.
• 31. Patsalos P.N.: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 2000; 85: 77–85.
• 32. Nicolas J.M., Collart P., Gerin B. i wsp.: In vitro evaluation of potential drug interactions with levetiracetam, a new antiepi­leptic agent. Drug Metab. Dispos. 1999; 27: 250–254.
• 33. Toublanc N., Lacroix B.D., Yamamoto J.: Development of an integrated population pharmacokinetic model for oral leveti­racetam in populations of various ages and ethnicities. Drug Metab. Pharmacokinet. 2014; 29: 61–68.
• 34. Grant R., Shorvon S.D.: Efficacy and tolerability of 1000–4000 mg per day of levetiracetam as add-on therapy in patients with refrac­tory epilepsy. Epilepsy Res. 2000; 42: 89–95.
• 35. Weinstock A., Ruiz M., Gerard D. i wsp.: Prospective open-label, single-arm, multicenter, safety, tolerability, and phar­macokinetic studies of intravenous levetiracetam in children with epilepsy. J. Child Neurol. 2013; 28: 1423–1429.
• 36. Reisinger T.L., Newman M., Loring D.W. i wsp.: Antiepilep­tic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013; 29: 13–18.
• 37. Dahlin M.G., Wide K., Ohman I.: Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr. Neurol. 2010; 43: 231–235.
• 38. Italiano D., Perucca E.: Clinical pharmacokinetics of new-gen­eration antiepileptic drugs at the extremes of age: an update. Clin. Pharmacokinet. 2013; 52: 627–645.
• 39. Sharpe C.M., Capparelli E.V., Mower A. i wsp.: A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr. Res. 2012; 72: 43–49.
• 40. Contin M., Mohamed S., Albani F. i wsp.: Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. Epilepsy Res. 2012; 98: 130–134.
• 41. Contin M., Albani F., Riva R., Baruzzi A.: Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug. Monit. 2004; 26: 375–379.
• 42. Johannessen Landmark C., Baftiu A., Tysse I. i wsp.: Pharma­cokinetic variability of four newer antiepileptic drugs, lamotrig­ine, levetiracetam, oxcarbazepine, and topiramate: a compari­son of the impact of age and comedication. Ther. Drug. Monit. 2012; 34: 440–445.
• 43. Spencer D.D., Jacobi J., Juenke J.M. i wsp.: Steady-state pharmacokinetics of intravenous levetiracetam in neurocriti­cal care patients. Pharmacotherapy 2011; 31: 934–941.
• 44. Meierkord H., Boon P., Engelsen B. i wsp.; European Feder­ation of Neurological Societies: EFNS guideline on the man­agement of status epilepticus in adults. Eur. J. Neurol. 2010; 17: 348–355.
• 45. Cook A.M., Castle A., Green A. i wsp.: Practice variations in the management of status epilepticus. Neurocrit. Care 2012; 17: 24–30.
• 46. Misra U.K., Kalita J., Maurya P.K.: Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J. Neurol. 2012; 259: 645–648.
• 47. Berning S., Boesebeck F., van Baalen A., Kellinghaus C.: Intravenous levetiracetam as treatment for status epilepticus. J. Neurol. 2009; 256: 1634–1642.
• 48. Lacerda G., Krummel T., Sabourdy C. i wsp.: Optimizing ther­apy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67 (supl. 4): S28–S33.
• 49. Brockmöller J., Thomsen T., Wittstock M. i wsp.: Pharmacoki­netics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 2005; 77: 529–541.
• 50. Bilo L., Meo R., de Leva M.F. i wsp.: Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Clin. Neuropharmacol. 2008; 31: 221–225.
• 51. Glass G.A., Stankiewicz J., Mithoefer A. i wsp.: Levetirace­tam for seizures after liver transplantation. Neurology 2005; 64: 1084–1085.
• 52. Chabolla D.R., Harnois D.M., Meschia J.F.: Levetiracetam monotherapy for liver transplant patients with seizures. Trans­plant. Proc. 2003; 35: 1480–1481.
• 53. Franzoni E., Sarajlija J., Garone C. i wsp.: No kinetic interac­tion between levetiracetam and cyclosporine: a case report. J. Child Neurol. 2007; 22: 440–442.
• 54. Brodtkorb E., Mula M.: Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67 (supl. 4): S39–S44.
• 55. Beavis J., Meek A., Felce D., Kerr M.: A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabili­ties. Seizure 2009; 18: 279–284.
• 56. Hurtado B., Koepp M.J., Sander J.W., Thompson P.J.: The impact of levetiracetam on challenging behavior. Epilepsy Behav. 2006; 8: 588–592.
• 57. Brodtkorb E., Klees T.M., Nakken K.O. i wsp.: Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav. 2004; 5: 231–235.
• 58. Aldenkamp A.P., Arzimanoglou A., Reijs R., Van Mil S.: Opti­mizing therapy of seizures in children and adolescents with ADHD. Neurology 2006; 67 (supl. 4): S49–S51.
• 59. Bakke K.A., Larsson P.G., Eriksson A.S., Eeg-Olofsson O.: Levetiracetam reduces the frequency of interictal epileptiform discharges during NREM sleep in children with ADHD. Eur. J. Paediatr. Neurol. 2011; 15: 532–538.
• 60. Gagliano A., Aricò I., Calarese T. i wsp.: Restless Leg Syn­drome in ADHD children: levetiracetam as a reasonable ther­apeutic option. Brain Dev. 2011; 33: 480–486.
• 61. Larsson P.G., Bakke K.A., Bjørnæs H. i wsp.: The effect of leve­tiracetam on focal nocturnal epileptiform activity during sleep – a placebo-controlled double-blind cross-over study. Epilepsy Behav. 2012; 24: 44–48.
• 62. Kellinghaus C., Engbring C., Kovac S. i wsp.: Frequency of sei­zures and epilepsy in neurological HIV-infected patients. Sei­zure 2008; 17: 27–33.
• 63. Birbeck G.L., French J.A., Perucca E. i wsp.; Quality Standards Subcommittee of the American Academy of Neurology; Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy: Evidence-based guideline: Antiepileptic drug selection for people with HIV/ AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the Interna­tional League Against Epilepsy. Neurology 2012; 78: 139–145.
• 64. Siddiqi O., Birbeck G.L.: Safe treatment of seizures in the setting of HIV/AIDS. Curr. Treat. Options Neurol. 2013; 15: 529–543.
• 65. Hauser W.A., Annegers J.F., Kurland L.T.: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–468.
• 66. Burn J., Dennis M., Bamford J. i wsp.: Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997; 315: 1582–1587.
• 67. So E.L., Annegers J.F., Hauser W.A. i wsp.: Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–355.
• 68. Arboix A., Comes E., García-Eroles L. i wsp.: Prognostic value of very early seizures for in-hospital mortality in athero­thrombotic infarction. Eur. Neurol. 2003; 50: 78–84.
• 69. Shinton R.A., Gill J.S., Melnick S.C. i wsp.: The frequency, characteristics and prognosis of epileptic seizures at the onset of stroke. J. Neurol. Neurosurg. Psychiatry 1988; 51: 273–276.
• 70. Kilpatrick C.J., Davis S.M., Tress B.M. i wsp.: Epileptic sei­zures in acute stroke. Arch. Neurol. 1990; 47: 157–160.
• 71. Reith J., Jørgensen H.S., Nakayama H. i wsp.: Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997; 28: 1585–1589.
• 72. Ryvlin P., Montavont A., Nighoghossian N.: Optimizing thera­py of seizures in stroke patients. Neurology 2006; 67 (supl. 4): S3–S9.
• 73. Belcastro V., Pierguidi L., Tambasco N.: Levetiracetam in brain ischemia: clinical implications in neuroprotection and preven­tion of post-stroke epilepsy. Brain Dev. 2011; 33: 289–293.
• 74. Kilicdag H., Daglıoglu K., Erdogan S. i wsp.: The effect of leve­tiracetam on neuronal apoptosis in neonatal rat model of hypox­ic ischemic brain injury. Early Hum. Dev. 2013; 89: 355–360.
• 75.Gilad R.: Management of seizures following a stroke: what are the options? Drugs Aging 2012; 29: 533–538.
• 76. Consoli D., Bosco D., Postorino P. i wsp.; EPIC Study: Leveti­racetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc. Dis. 2012; 34: 282–289.
• 77. Kutlu G., Gomceli Y.B., Unal Y., Inan L.E.: Levetiracetam monotherapy for late poststroke seizures in the elderly. Epi­lepsy Behav. 2008; 13: 542–544.
• 78. Belcastro V., Costa C., Galletti F. i wsp.: Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res. 2008; 82: 223–226.
• 79. Harden C.L., Leppik I.: Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006; 67 (supl. 4): S56–S58.
• 80. Coulam C.B., Annegers J.F.: Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519–525.
• 81. Ragueneau-Majlessi I., Levy R.H., Janik F.: Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002; 43: 697–702.
• 82. Sabers A., Christensen J.: No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011; 95: 277–279.

• Document Type: article